Impact of Guidelines on Hypertension Control in the Elderly

Page: [1952 - 1959] Pages: 8

  • * (Excluding Mailing and Handling)

Abstract

Background: Hypertension control is a crucial measure to reduce cardiovascular (CV) risk, and blood pressure (BP) treatment targets have been recently revised to address this issue. However, achieving the recommended goal may be challenging.

Objective: We aimed to assess the prevalence of uncontrolled hypertension, according to the US hypertension guidelines, among elderly participants in an Italian nationwide epidemiological survey, the relevant clinical correlates, and the agreement with the application of the European guidelines.

Methods: Elderly (≥65y) volunteers enrolled in an Italian nationwide survey underwent BP measurement using standard protocols. Uncontrolled hypertension was defined as BP≥130/80 mmHg. Agreement of this definition with those from European guidelines (≥140/90 mmHg; ≥140/80 mmHg) was tested using Cohen’s kappa. Selfreported information on modifiable/non-modifiable CV risk factors was also collected.

Results: Of the 13,162 treated hypertensive elderly, 69.8% had uncontrolled hypertension. They tended to be overweight/obese men with diabetes. Overall agreement between US and European guidelines was poor to good (κ = 0.289, p<0.001 and κ = 0.691, p<0.001 based on the 140/90 and 140/80 mmHg threshold, respectively). Elderly participants with controlled hypertension were more likely to report a history of CV or chronic kidney disease. No difference in lifestyle habits was observed by BP control status.

Conclusion: Real-world data identify limited concordance between guidelines in terms of BP target achievement among older hypertensive Italians and highlights the need to spread awareness of the CV risk, especially in the presence of diabetes and obesity.

Keywords: Hypertension, life style, risk reduction behavior, cardiovascular diseases, patient, care planning, surveys and questionnaires.

[1]
World Health Organization. Global Action Plan For The Prevention And Control Of Noncommunicable Diseases 2013-2020. Available at: https://www.who.int/publications/i/item/9789241506236
[2]
Del Pinto R, Pagliacci S, De Feo M, Grassi D, Ferri C. Italian Society of Hypertension and Federfarma. Prevalence of hypertension and associated cardiovascular risk factors among pharmacies customers: an Italian nationwide epidemiological survey. Eur J Prev Cardiol 2020; 27(11): 1228-30.
[PMID: 31116573]
[3]
Global Recommendations on Physical Activity for Health. Geneva: World Health Organization 2015. Available at: https://www.who.int/publications/i/item/9789241599979
[4]
Diet, nutrition and the prevention of chronic diseases. A report of the WHO Study Group on Diet, Nutrition and Prevention of Noncommunicable Diseases. Nutr Rev 1991; 49(10): 291-301.
[PMID: 1749527]
[5]
[6]
Fryar CD, Ostchega Y, Hales CM, Zhang G, Kruszon-Moran D. Hypertension Prevalence and Control Among Adults: United States, 2015-2016. NCHS Data Brief 2017; (289): 1-8.
[PMID: 29155682]
[7]
Borghi C, Tubach F, De Backer G, et al. Lack of control of hypertension in primary cardiovascular disease prevention in Europe: Results from the EURIKA study. Int J Cardiol 2016; 218: 83-8.
[http://dx.doi.org/10.1016/j.ijcard.2016.05.044] [PMID: 27232917]
[8]
Elliott WJ. What factors contribute to the inadequate control of elevated blood pressure? J Clin Hypertens (Greenwich) 2008; 10(1)(Suppl. 1): 20-6.
[http://dx.doi.org/10.1111/j.1524-6175.2007.08028.x] [PMID: 18174780]
[9]
Del Pinto R, Wright JT, Monaco A, Pietropaoli D, Ferri C. Vitamin D and blood pressure control among hypertensive adults: results from NHANES 2001-2014. J Hypertens 2020; 38(1): 150-8.
[http://dx.doi.org/10.1097/HJH.0000000000002231] [PMID: 31503133]
[10]
Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2018; 138(17): e484-594.
[PMID: 30354654]
[11]
Williams B, Mancia G, Spiering W, et al. ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; 39(33): 3021-104.
[http://dx.doi.org/10.1093/eurheartj/ehy339] [PMID: 30165516]
[12]
Mancia G, Fagard R, Narkiewicz K, et al. Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31(7): 1281-357.
[http://dx.doi.org/10.1097/01.hjh.0000431740.32696.cc] [PMID: 23817082]
[13]
Perk J, De Backer G, Gohlke H, et al. European Association for Cardiovascular Prevention & Rehabilitation (EACPR); ESC Committee for Practice Guidelines (CPG). European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012; 33(13): 1635-701.
[http://dx.doi.org/10.1093/eurheartj/ehs092] [PMID: 22555213]
[14]
Armstrong RA. When to use the Bonferroni correction. Ophthalmic Physiol Opt 2014; 34(5): 502-8.
[http://dx.doi.org/10.1111/opo.12131] [PMID: 24697967]
[15]
Ranganathan P, Pramesh CS, Aggarwal R. Common pitfalls in statistical analysis: Measures of agreement. Perspect Clin Res 2017; 8(4): 187-91.
[http://dx.doi.org/10.4103/picr.PICR_123_17] [PMID: 29109937]
[16]
Fleiss JL, Levin B, Paik MC, Eds. The Measurement of Interrater Agreement Statistical Methods for Rates and Proportions. Hoboken, NJ, USA: John Wiley & Sons, Inc. 2003; pp. 598-626.
[http://dx.doi.org/10.1002/0471445428.ch18]
[17]
Altman DG. Practical Statistics for Medical Research. CRC Press 1990.
[http://dx.doi.org/10.1201/9780429258589]
[18]
Franklin SS. Ageing and hypertension: the assessment of blood pressure indices in predicting coronary heart disease. J Hypertens Suppl 1999; 17(5): S29-36.
[PMID: 10706323]
[19]
Del Pinto R, Grassi D, Properzi G, Desideri G, Ferri C. Low Density Lipoprotein (LDL) Cholesterol as a Causal Role for Atherosclerotic Disease: Potential Role of PCSK9 Inhibitors. High Blood Press Cardiovasc Prev 2019; 26(3): 199-207.
[http://dx.doi.org/10.1007/s40292-019-00323-7] [PMID: 31236902]
[20]
Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels - updated overview and meta-analyses of randomized trials. J Hypertens 2016; 34(4): 613-22.
[http://dx.doi.org/10.1097/HJH.0000000000000881] [PMID: 26848994]
[21]
Del Pinto R, Ferri C. Hypertension Management at Older Age: An Update. High Blood Press Cardiovasc Prev 2019; 26(1): 27-36.
[http://dx.doi.org/10.1007/s40292-018-0290-z] [PMID: 30467638]
[22]
Verdecchia P, Angeli F, Gentile G, Reboldi G. More Versus Less Intensive Blood Pressure-Lowering Strategy: Cumulative Evidence and Trial Sequential Analysis. Hypertension 2016; 68(3): 642-53.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.116.07608] [PMID: 27456518]
[23]
Kjeldsen SE, Narkiewicz K, Burnier M, Oparil S. Intensive blood pressure lowering prevents mild cognitive impairment and possible dementia and slows development of white matter lesions in brain: the SPRINT Memory and Cognition IN Decreased Hypertension (SPRINT MIND) study. Blood Press 2018; 27(5): 247-8.
[http://dx.doi.org/10.1080/08037051.2018.1507621] [PMID: 30175661]
[24]
Juraschek SP, Taylor AA, Wright JT Jr, et al. SPRINT Research Group. Orthostatic Hypotension, Cardiovascular Outcomes, and Adverse Events: Results From SPRINT. Hypertension 2020; 75(3): 660-7.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.119.14309] [PMID: 31983312]
[25]
Wright JT Jr, Williamson JD, Whelton PK, et al. SPRINT Research Group. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med 2015; 373(22): 2103-16.
[http://dx.doi.org/10.1056/NEJMoa1511939] [PMID: 26551272]
[26]
McFarlane SI, Castro J, Kaur J, et al. Control of blood pressure and other cardiovascular risk factors at different practice settings: outcomes of care provided to diabetic women compared to men. J Clin Hypertens (Greenwich) 2005; 7(2): 73-80.
[http://dx.doi.org/10.1111/j.1524-6175.2005.03869.x] [PMID: 15722651]
[27]
Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004; 291(3): 335-42.
[http://dx.doi.org/10.1001/jama.291.3.335] [PMID: 14734596]
[28]
Stults B. Management of Hypertension in Diabetes. Diabetes Spectr 2006; 19: 25-31.
[http://dx.doi.org/10.2337/diaspect.19.1.25]
[29]
Brown MJ, Castaigne A, de Leeuw PW, et al. Influence of diabetes and type of hypertension on response to antihypertensive treatment. Hypertension 2000; 35(5): 1038-42.
[http://dx.doi.org/10.1161/01.HYP.35.5.1038] [PMID: 10818061]
[30]
Merz CNB, Buse JB, Tuncer D, Twillman GB. Physician attitudes and practices and patient awareness of the cardiovascular complications of diabetes. J Am Coll Cardiol 2002; 40(10): 1877-81.
[http://dx.doi.org/10.1016/S0735-1097(02)02529-9] [PMID: 12446074]
[31]
Lai S, Mariotti A, Coppola B, et al. Uricemia and homocysteinemia: nontraditional risk factors in the early stages of chronic kidney disease-preliminary data. Eur Rev Med Pharmacol Sci 2014; 18(7): 1010-7.
[PMID: 24763881]
[32]
Kemps H, Kränkel N, Dörr M, et al. Exercise training for patients with type 2 diabetes and cardiovascular disease: What to pursue and how to do it. A Position Paper of the European Association of Preventive Cardiology (EAPC). Eur J Prev Cardiol 2019; 26(7): 709-27.
[http://dx.doi.org/10.1177/2047487318820420] [PMID: 30642190]
[33]
Catapano AL, Graham I, De Backer G, et al. Additional Contributor. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Rev Esp Cardiol (Engl Ed) 2017; 70(2): 115.
[http://dx.doi.org/10.1016/j.rec.2017.01.002] [PMID: 29389351]
[34]
Grundy SM, Stone NJ, Bailey AL, et al. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019; 73(24): 3168-209.
[35]
Borjesson M, Dellborg M, Niebauer J, et al. Recommendations for participation in leisure time or competitive sports in athletes-patients with coronary artery disease: a position statement from the Sports Cardiology Section of the European Association of Preventive Cardiology (EAPC). Eur Heart J 2019; 40(1): 13-8.
[http://dx.doi.org/10.1093/eurheartj/ehy408] [PMID: 30052887]
[36]
Leitzmann MF, Park Y, Blair A, et al. Physical activity recommendations and decreased risk of mortality. Arch Intern Med 2007; 167(22): 2453-60.
[http://dx.doi.org/10.1001/archinte.167.22.2453] [PMID: 18071167]
[37]
Rossi A, Dikareva A, Bacon SL, Daskalopoulou SS. The impact of physical activity on mortality in patients with high blood pressure: a systematic review. J Hypertens 2012; 30(7): 1277-88.
[http://dx.doi.org/10.1097/HJH.0b013e3283544669] [PMID: 22573122]
[38]
Del Pinto R, Pietropaoli D, Monaco A, Desideri G, Ferri C, Grassi D. Non-pharmacological Strategies Against Systemic Inflammation: Molecular Basis and Clinical Evidence. Curr Pharm Des 2020; 26(22): 2620-9.
[http://dx.doi.org/10.2174/1381612826666200403122600] [PMID: 32242777]
[39]
Mueller NT, Noya-Alarcon O, Contreras M, Appel LJ, Dominguez-Bello MG. Association of Age With Blood Pressure Across the Lifespan in Isolated Yanomami and Yekwana Villages. JAMA Cardiol 2018; 3(12): 1247-9.
[http://dx.doi.org/10.1001/jamacardio.2018.3676] [PMID: 30427998]
[40]
Ding M, Bhupathiraju SN, Satija A, van Dam RM, Hu FB. Long-term coffee consumption and risk of cardiovascular disease: a systematic review and a dose-response meta-analysis of prospective cohort studies. Circulation 2014; 129(6): 643-59.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.113.005925] [PMID: 24201300]
[41]
Greyling A, Ras RT, Zock PL, et al. The effect of black tea on blood pressure: a systematic review with meta-analysis of randomized controlled trials. PLoS One 2014; 9(7): e103247.
[http://dx.doi.org/10.1371/journal.pone.0103247] [PMID: 25079225]
[42]
Abumweis SS, Barake R, Jones PJH. Plant sterols/stanols as cholesterol lowering agents: A meta-analysis of randomized controlled trials. Food Nutr Res 2008; 52.
[http://dx.doi.org/10.3402/fnr.v52i0.1811] [PMID: 19109655]
[43]
Piepoli MF, Hoes AW, Agewall S, et al. Authors/Task Force Members. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis 2016; 252: 207-74.
[http://dx.doi.org/10.1016/j.atherosclerosis.2016.05.037] [PMID: 27664503]
[44]
Tonetti MS, D’Aiuto F, Nibali L, et al. Treatment of periodontitis and endothelial function. N Engl J Med 2007; 356(9): 911-20.
[http://dx.doi.org/10.1056/NEJMoa063186] [PMID: 17329698]
[45]
Pietropaoli D, Del Pinto R, Ferri C, et al. Poor Oral Health and Blood Pressure Control Among US Hypertensive Adults. Hypertension 2018; 72(6): 1365-73.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.118.11528] [PMID: 30540406]
[46]
Del Pinto R, Ferri C. Inflammation-Accelerated Senescence and the Cardiovascular System: Mechanisms and Perspectives. Int J Mol Sci 2018; 19(12): E3701.
[http://dx.doi.org/10.3390/ijms19123701] [PMID: 30469478]
[47]
Rydén L, Grant PJ, Anker SD, et al. Authors/Task Force Members; ESC Committee for Practice Guidelines (CPG); Document Reviewers. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 2013; 34(39): 3035-87.
[http://dx.doi.org/10.1093/eurheartj/eht108] [PMID: 23996285]
[48]
Pietropaoli D, Del Pinto R, Ferri C, et al. Association between periodontal inflammation and hypertension using periodontal inflamed surface area and bleeding on probing. J Clin Periodontol 2020; 47(2): 160-72.
[http://dx.doi.org/10.1111/jcpe.13216] [PMID: 31680283]
[49]
Muñoz Aguilera E, Suvan J, Buti J, et al. Periodontitis is associated with hypertension: a systematic review and meta-analysis. Cardiovasc Res 2020; 116(1): 28-39.
[http://dx.doi.org/10.1093/cvr/cvz201] [PMID: 31549149]
[50]
Pietropaoli D, Monaco A, D’Aiuto F, et al. Active gingival inflammation is linked to hypertension. J Hypertens 2020; 38(10): 2018-27.
[http://dx.doi.org/10.1097/HJH.0000000000002514]
[51]
Del Pinto R, Pietropaoli D, Munoz-Aguilera E, et al. Periodontitis and Hypertension: Is the Association Causal? High Blood Press Cardiovasc Prev 2020; 27(4): 281-9.
[http://dx.doi.org/10.1007/s40292-020-00392-z] [PMID: 32500479]
[52]
Pietropaoli D, Del Pinto R, Ferri C, Ortu E, Monaco A. Definition of hypertension-associated oral pathogens in NHANES. J Periodontol 2019; 90(8): 866-76.
[http://dx.doi.org/10.1002/JPER.19-0046] [PMID: 31090063]
[53]
Manson JE, Cook NR, Lee I-M, et al. VITAL Research Group. Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer. N Engl J Med 2019; 380(1): 23-32.
[http://dx.doi.org/10.1056/NEJMoa1811403] [PMID: 30415637]
[54]
Manson JE, Cook NR, Lee I-M, et al. VITAL Research Group. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. N Engl J Med 2019; 380(1): 33-44.
[http://dx.doi.org/10.1056/NEJMoa1809944] [PMID: 30415629]
[55]
Del Pinto R, Ferri C, Cominelli F, Vitamin D, Vitamin D. Axis in Inflammatory Bowel Diseases: Role, Current Uses and Future Perspectives. Int J Mol Sci 2017; 18(11): E2360.
[http://dx.doi.org/10.3390/ijms18112360] [PMID: 29112157]
[56]
Estébanez N, Gómez-Acebo I, Palazuelos C, Llorca J, Dierssen-Sotos T. Vitamin D exposure and Risk of Breast Cancer: a meta-analysis. Sci Rep 2018; 8(1): 9039.
[http://dx.doi.org/10.1038/s41598-018-27297-1] [PMID: 29899554]
[57]
Afzal S, Brøndum-Jacobsen P, Bojesen SE, Nordestgaard BG. Vitamin D concentration, obesity, and risk of diabetes: a mendelian randomisation study. Lancet Diabetes Endocrinol 2014; 2(4): 298-306.
[http://dx.doi.org/10.1016/S2213-8587(13)70200-6] [PMID: 24703048]
[58]
Scragg R, Sowers M, Bell C. Serum 25-hydroxyvitamin D, ethnicity, and blood pressure in the Third National Health and Nutrition Examination Survey. Am J Hypertens 2007; 20(7): 713-9.
[http://dx.doi.org/10.1016/j.amjhyper.2007.01.017] [PMID: 17586404]
[59]
Martins D, Wolf M, Pan D, et al. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med 2007; 167(11): 1159-65.
[http://dx.doi.org/10.1001/archinte.167.11.1159] [PMID: 17563024]
[60]
Wang TJ, Pencina MJ, Booth SL, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008; 117(4): 503-11.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.107.706127] [PMID: 18180395]
[61]
Daraghmeh AH, Bertoia ML, Al-Qadi MO, Abdulbaki AM, Roberts MB, Eaton CB. Evidence for the vitamin D hypothesis: The NHANES III extended mortality follow-up. Atherosclerosis 2016; 255: 96-101.
[http://dx.doi.org/10.1016/j.atherosclerosis.2016.04.007] [PMID: 27855294]
[62]
Sergi C, Chiu B, Feulefack J, Shen F, Chiu B. Usefulness of resveratrol supplementation in decreasing cardiometabolic risk factors comparing subjects with metabolic syndrome and healthy subjects with or without obesity: meta-analysis using multinational, randomised, controlled trials. Arch Med Sci Atheroscler Dis 2020; 5: e98-e111.
[http://dx.doi.org/10.5114/amsad.2020.95884] [PMID: 32529112]
[63]
Sahebkar A. Effects of resveratrol supplementation on plasma lipids: a systematic review and meta-analysis of randomized controlled trials. Nutr Rev 2013; 71(12): 822-35.
[http://dx.doi.org/10.1111/nure.12081] [PMID: 24111838]
[64]
Sahebkar A, Serban C, Ursoniu S, et al. Lipid and Blood Pressure Meta-analysis Collaboration Group. Lack of efficacy of resveratrol on C-reactive protein and selected cardiovascular risk factors-Results from a systematic review and meta-analysis of randomized controlled trials. Int J Cardiol 2015; 189: 47-55.
[http://dx.doi.org/10.1016/j.ijcard.2015.04.008] [PMID: 25885871]
[65]
Del Pinto R, Pietropaoli D, Ferri C. Diastolic blood pressure and risk profile in renal and cardiovascular diseases. Results from the SPRINT trial. J Am Soc Hypertens 2018; 12(7): 513-523.e3.
[http://dx.doi.org/10.1016/j.jash.2018.04.004] [PMID: 29803637]
[66]
Townsend RR, Chang TI, Cohen DL, et al. SPRINT Study Research Group. Orthostatic changes in systolic blood pressure among SPRINT participants at baseline. J Am Soc Hypertens 2016; 10(11): 847-56.
[http://dx.doi.org/10.1016/j.jash.2016.08.005] [PMID: 27665708]
[67]
Del Pinto R, Pietropaoli D, Dobre M, Ferri C. Prognostic importance of long-term SBP variability in high-risk hypertension. J Hypertens 2020; 38(11): 2237-44.
[http://dx.doi.org/10.1097/HJH.0000000000002552] [PMID: 32649637]
[68]
Del Pinto R, Pietropaoli D, Russomando U, Evangelista P, Ferri C. Health status of Afro-Asian refugees in an Italian urban area: a cross-sectional monocentric study. Public Health 2018; 158: 176-82.
[http://dx.doi.org/10.1016/j.puhe.2018.03.011] [PMID: 29628202]